Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TX103 CAR-T
- Development stage
- Unknown
- Lead developer
- Fuzhou Tuoxin Tiancheng Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intrathecal
01
Overview
TX103 CAR-T is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting B7-H3 (CD276), developed by Fuzhou Tuoxin Tiancheng Biological Technology (T-MAXIMUM). B7-H3 is a transmembrane protein frequently overexpressed in various solid tumors, including high-grade gliomas, while showing limited expression in normal tissues, making it an attractive therapeutic target. TX103 is specifically designed for the treatment of relapsed or progressive grade 4 glioma. The therapy is typically administered via an intracerebroventricular route (e.g., through an Ommaya reservoir) to bypass the blood-brain barrier and directly target the tumor microenvironment within the central nervous system. It is currently undergoing Phase 1 clinical evaluation to assess its safety, tolerability, and preliminary efficacy in adult patients.
- Other names
- B7-H3-targeted CAR-T cellsB-7-H3-targeted CAR-T cellsB 7-H3-targeted CAR-T cells
02
Targets
B7-H3
Beyond the preview
Go deeper on TX103 CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TX103 CAR-T.